Acrux delivers sweet medicine

The biotech company posted a boost of sales from its testosterone treatment product and is well positioned for its milestone payment from Eli Lilly this year.

Shares in Acrux (ACR) jumped 1.4% to $3.55 this morning on news of a material increase in sales of its spray on testosterone treatment.

Pharmaceutical giant Eli Lily, which is the exclusive distributor of Acrux’s Axiron, reported sales of $US47 million in the June quarter, or a 27% increase from the previous quarter and a three-fold increase in nine months.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles